The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Mechanisms of aromatase inhibitor resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Research works printed but not linked: 15
- Ellis, M. J. et al. Z1031B neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%. Cancer Res. 72, PD07-01 (2012). · doi:10.1158/0008-5472.sabcs12-pd07-01
- Ellis, M. J. et al. Tumor Ki67 proliferation index within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders. Cancer Res. 69, 78 (2009). · doi:10.1158/0008-5472.sabcs-09-78
- Goncalves, R. et al. A Ki67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. J. Pharmacogenomics Pharmacoproteomics 5, 5 (2014).
- Fan, P. et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur. J. Cancer 50, 457–468 (2014). · doi:10.1016/j.ejca.2013.10.001
- Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809 (2008). · doi:10.1038/ng0708-809a
- Horlings, H. M. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 807–808 (2008). · doi:10.1038/ng0708-807
- Holst, F. et al. On the evidence for ESR1 amplification in breast cancer. Nature Rev. Cancer 12, 149 (2012). · doi:10.1038/nrc3093-c3
- Moelans, C. B. et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol. (Amst.) 33, 13–18 (2010). · doi:10.1155/2010/619180
- Kaufman, P. A. et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 70, S1–S4 (2010). · doi:10.1158/0008-5472.can-09-4246
- Hortobagyi, G. N. et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J. Clin. Oncol. 31, LBA509 (2013). · doi:10.1200/jco.2013.31.18_suppl.lba509
- Giacinti, L. et al. Scriptaid effects on breast cancer cell lines. J. Cell. Physiol. 227, 3426–3433 (2012). · doi:10.1002/jcp.24043
- Marks, P. A. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 3, 534–535 (2004). · doi:10.4161/cc.3.5.824
- Bianchini, G. et al. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. J. Clin. Oncol. 30, 545 (2012). · doi:10.1200/jco.2012.30.4_suppl.545
- Piccart, M. et al. Assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing. Ann. Oncol. 24 (Suppl. 3), 25–26 (2013). · doi:10.1093/annonc/mdt083.3
- Adelson, K. B., Raptis, G., Sparano, J. & Germain, D. Randomized phase II study of fulvestrant versus fulvestrant plus bortezomib in postmenopausal women with estrogen receptor (ER) positive, aromatase-inhibitor (AI) resistant metastatic breast cancer (MBC): New York Cancer Consortium trial P8457. Cancer Res. 71, OT3-01-01 (2014). · doi:10.1158/0008-5472.sabcs11-ot3-01-01
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Metadata
- Authors
- Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-04-24
- Volume
- 15
- Issue
- 5
- Pages
- 261-275
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1992533338
- Cited by
- 407
- References
- 174
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of aromatase inhibitor resistance. https://app.cochat.ai/papers/10.1038/nrc3920
- The paper
- Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J. (2015). Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. https://doi.org/10.1038/nrc3920
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.